Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
The Lancet. Oncology|December 25, 2025
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trialKarim Fizazi, Fred Saad, Teresa Alonso-Gordoa, et al.
The New England Journal of Medicine|September 16, 2024
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder CancerThomas Powles, James W F Catto, Matthew D Galsky, et al.
Frontiers in Immunology|March 12, 2026
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?Linda Cerbone, Giandomenico Roviello, Fabio Calabrò, et al.
Prostate Cancer and Prostatic Diseases|January 7, 2026
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 studyThomas Büttner, Mimma Rizzo, Laura Bernal Vaca, et al.
Cancers|March 10, 2022
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II StudiesManish A Shah, Anghel Adrian Udrea, Igor Bondarenko, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinationsLorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
The Lancet. Oncology|March 1, 2023
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label studyToni K Choueiri, Masatoshi Eto, Robert Motzer, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 studyCamillo Porta, Francesco Massari, Tarek Taha, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological reviewMarit Ahrens, John Haanen, Laurence Albiges, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Pageof 14